Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT04933916
PHASE1/PHASE2

Study of EMB-001 as a Potential Smoking Cessation Treatment

Sponsor: Embera NeuroTherapeutics, Inc.

View on ClinicalTrials.gov

Summary

EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This is an open-label study in up to 50 adult subjects to help smokers abstain from smoking during a 12-week trial period.

Official title: Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

Key Details

Gender

All

Age Range

21 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

13

Start Date

2021-06-10

Completion Date

2023-05-01

Last Updated

2026-11-05

Healthy Volunteers

No

Interventions

DRUG

EMB-001

Combination product metyrapone and oxazepam

Locations (2)

Embera Site

Miami Lakes, Florida, United States

Rose Research Center

Raliegh, North Carolina, United States